查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602810

抗血管內皮生長因子治療市場：依治療類型、給藥途徑、適應症分類 - 全球預測 2025-2030

Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), Route of Administration (Intravitreal Injections, Oral Administration), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗血管內皮生長因子治療市場估值為84.9億美元，預計2024年將達90.1億美元，複合年成長率為8.85%，2030年將達153億美元，預計將達80美元百萬。

抗血管內皮生長因子（VEGF）療法在治療與血管生長異常相關的疾病中發揮重要作用，例如老齡化黃斑部病變（AMD）、糖尿病視網膜病變和某些癌症。其作用範圍是抑制參與血管生成的VEGF蛋白並阻止疾病進展。隨著血管相關疾病的盛行率隨著人口老化而增加，對抗 VEGF 療法等有效治療方法的需求變得顯而易見。這些療法主要應用於眼科和腫瘤科，為醫院、診所和專業醫療中心等最終用戶提供服務。關鍵的成長要素包括目標疾病盛行率的增加、生技藥品的進步以及有前景的化合物的強大管道。該公司將透過專注於生物相似藥開發、新興市場的地理擴張以及利用基因組見解來最佳化治療結果的個人化醫療方法來抓住潛在的商機。

主要市場統計
基準年[2023] 84.9億美元
預測年份 [2024] 90.1億美元
預測年份 [2030] 153.8億美元
複合年成長率（%） 8.85%

然而，市場面臨著治療成本高、專利到期導致生物相似藥競爭以及與長期治療相關的潛在副作用等挑戰。監管障礙和生物製藥製造的複雜性為市場擴張帶來了進一步的挑戰。儘管存在這些障礙，創新仍然很重要。緩釋性、聯合治療和新型遞送系統（例如玻璃體內注射和眼內植入）等領域代表了有前景的研究途徑。此外，整合遠端醫療等數位技術來監測治療效果可以加強病患管理並減輕醫療負擔。該市場的特點是動態競爭、不斷進步以及大力推動常見障礙的永續解決方案。強調製藥公司、學術機構和生物技術公司之間的合作研究可以加速疾病機制理解的突破以及更有效的抗VEGF療法的研發。透過了解這些趨勢並應對不斷變化的監管環境，公司可以對自己進行策略性定位，以便在這個不斷發展的治療領域中實現顯著成長。

市場動態：快速發展的抗血管內皮生長因子治療市場的關鍵市場洞察

供需的動態交互作用正在改變抗血管內皮生長因子治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 眼科疾病盛行率上升
    • 患有眼科疾病的老年人口增加
    • 提高抗 VEGF 治療的認知
  • 市場限制因素
    • 抗 VEGF 治療的不利報銷情況
  • 市場機會
    • 持續研究活動以開發先進的治療藥物
    • 監理藥品核准快速增加
  • 市場挑戰
    • 抗 VEGF 治療對眼內損傷的擔憂

波特五力：開拓抗血管內皮生長因子治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗血管內皮生長因子治療市場的外部影響

外部宏觀環境因素在塑造抗血管內皮生長因子治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗血管內皮生長因子治療藥物市場競爭狀況

抗血管內皮生長因子治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗血管內皮生長因子治療市場供應商的績效評估

FPNV定位矩陣是評估抗血管內皮生長因子治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪抗血管內皮生長因子治療市場的成功之路

抗血管內皮生長因子治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 眼科疾病盛行率上升
      • 患有眼科疾病的老年人數量增加
      • 提高抗 VEGF 治療的認知
    • 抑制因素
      • 抗 VEGF 治療的不利報銷情況
    • 機會
      • 旨在開發先進治療方法的持續研究活動
      • 監理藥品核准快速增加
    • 任務
      • 抗 VEGF 治療對眼內損傷的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的抗血管內皮生長因子治療藥物市場

  • 單株抗體
  • 蛋白酪氨酸激酶抑制劑

第7章抗血管內皮生長因子治療市場：依給藥途徑

  • 玻璃體內注射
  • 口服給藥

第8章按適應症分類的抗血管內皮生長因子治療市場

  • 糖尿病黃斑部水腫
  • 視網膜靜脈阻塞
  • 濕性老齡化黃斑部病變

第9章美洲抗血管內皮生長因子治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗血管內皮生長因子治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲抗血管內皮生長因子治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alteogen Inc.
  • Amgen Inc.
  • Arechar Healthcare
  • Aurobindo Pharma
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Cipla Ltd.
  • Coherus BioSciences, Inc.
  • Delphis Pharmaceutical India
  • F. Hoffmann-La Roche AG
  • Hetero Healthcare Limited
  • Intas Pharmaceuticals Ltd.
  • Natco Pharma Limited
  • Novartis AG
  • Pfenex Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis
  • Sandoz Canada Incorporated
  • Shilpa Medicare Ltd.
  • Sun Pharmaceutical Industries Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xbrane Biopharma
Product Code: MRR-B168537775F5

The Anti-vascular Endothelial Growth Factor Therapeutics Market was valued at USD 8.49 billion in 2023, expected to reach USD 9.01 billion in 2024, and is projected to grow at a CAGR of 8.85%, to USD 15.38 billion by 2030.

Anti-vascular endothelial growth factor (VEGF) therapeutics play a critical role in treating conditions related to abnormal blood vessel growth, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. Their scope involves inhibiting VEGF proteins responsible for angiogenesis, thus preventing disease progression. As the prevalence of vascular-related conditions escalates with an aging population, the necessity for effective treatments like anti-VEGF therapeutics has become more pronounced. These therapies find applications primarily in ophthalmology and oncology, serving end-users such as hospitals, clinics, and specialized healthcare centers. Key growth influencers include an increasing incidence of target disorders, advancements in biologics, and a robust pipeline of promising compounds. Companies can seize potential opportunities by focusing on biosimilars development, geographic expansion in emerging markets, and personalized medicine approaches, leveraging genomic insights to optimize therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 8.49 billion
Estimated Year [2024] USD 9.01 billion
Forecast Year [2030] USD 15.38 billion
CAGR (%) 8.85%

However, the market faces challenges, including high treatment costs, patent expiration leading to biosimilar competition, and potential adverse effects associated with long-term therapy use. Regulatory hurdles and the complexity of biologic drug manufacturing further challenge market expansion. Despite these impediments, innovation remains crucial; areas like extended-release formulations, combination therapies, and novel delivery systems such as intravitreal injections or ocular implants offer promising research avenues. Moreover, digital technology integration, like telemedicine for monitoring treatment efficacy, can enhance patient management and reduce healthcare burdens. The market is marked by dynamic competition, constant advancements, and a strong push towards sustainable solutions to commonly encountered barriers. Emphasizing collaborative research between pharmaceutical companies, academic institutions, and biotech firms can spur breakthroughs in understanding disease mechanisms and developing more effective anti-VEGF therapies. By staying attuned to these trends and adaptable to changing regulatory landscapes, businesses can strategically position themselves for substantial growth in this evolving therapeutic domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-vascular Endothelial Growth Factor Therapeutics Market

The Anti-vascular Endothelial Growth Factor Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of ophthalmic diseases
    • Increasing number of geriatric population with eye disorders
    • Growing awareness about anti-VEGF treatment
  • Market Restraints
    • Unfavorable reimbursement scenario for anti-VEGF treatment
  • Market Opportunities
    • Ongoing research activities to develop advanced therapeutics
    • Surge in drug approvals from regulatory bodies
  • Market Challenges
    • Concern regarding intraocular injuries in anti-VEGF treatment

Porter's Five Forces: A Strategic Tool for Navigating the Anti-vascular Endothelial Growth Factor Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-vascular Endothelial Growth Factor Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-vascular Endothelial Growth Factor Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-vascular Endothelial Growth Factor Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-vascular Endothelial Growth Factor Therapeutics Market

A detailed market share analysis in the Anti-vascular Endothelial Growth Factor Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-vascular Endothelial Growth Factor Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-vascular Endothelial Growth Factor Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-vascular Endothelial Growth Factor Therapeutics Market

A strategic analysis of the Anti-vascular Endothelial Growth Factor Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-vascular Endothelial Growth Factor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amgen Inc., Arechar Healthcare, Aurobindo Pharma, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Cipla Ltd., Coherus BioSciences, Inc., Delphis Pharmaceutical India, F. Hoffmann-La Roche AG, Hetero Healthcare Limited, Intas Pharmaceuticals Ltd., Natco Pharma Limited, Novartis AG, Pfenex Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Sandoz Canada Incorporated, Shilpa Medicare Ltd., Sun Pharmaceutical Industries Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xbrane Biopharma.

Market Segmentation & Coverage

This research report categorizes the Anti-vascular Endothelial Growth Factor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Type, market is studied across Monoclonal Antibodies and Tyrosine Kinase Inhibitors.
  • Based on Route of Administration, market is studied across Intravitreal Injections and Oral Administration.
  • Based on Indication, market is studied across Diabetic Macular Edema, Retinal Vein Occlusion, and Wet Age-Related Macular Degeneration.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of ophthalmic diseases
      • 5.1.1.2. Increasing number of geriatric population with eye disorders
      • 5.1.1.3. Growing awareness about anti-VEGF treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Unfavorable reimbursement scenario for anti-VEGF treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to develop advanced therapeutics
      • 5.1.3.2. Surge in drug approvals from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding intraocular injuries in anti-VEGF treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Tyrosine Kinase Inhibitors

7. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravitreal Injections
  • 7.3. Oral Administration

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Indication

  • 8.1. Introduction
  • 8.2. Diabetic Macular Edema
  • 8.3. Retinal Vein Occlusion
  • 8.4. Wet Age-Related Macular Degeneration

9. Americas Anti-vascular Endothelial Growth Factor Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-vascular Endothelial Growth Factor Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alteogen Inc.
  • 2. Amgen Inc.
  • 3. Arechar Healthcare
  • 4. Aurobindo Pharma
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Cipla Ltd.
  • 9. Coherus BioSciences, Inc.
  • 10. Delphis Pharmaceutical India
  • 11. F. Hoffmann-La Roche AG
  • 12. Hetero Healthcare Limited
  • 13. Intas Pharmaceuticals Ltd.
  • 14. Natco Pharma Limited
  • 15. Novartis AG
  • 16. Pfenex Inc.
  • 17. Pfizer Inc.
  • 18. Regeneron Pharmaceuticals Inc.
  • 19. Samsung Bioepis
  • 20. Sandoz Canada Incorporated
  • 21. Shilpa Medicare Ltd.
  • 22. Sun Pharmaceutical Industries Inc.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Viatris Inc.
  • 25. Xbrane Biopharma

LIST OF FIGURES

  • FIGURE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023